New to peptides? Start with the foundations ->
The dad-test answer
Retinol (a vitamin A derivative, not a peptide) has the deepest dermatology trial record - decades of split-face studies showing reduced fine lines, smoother skin, and increased collagen. GHK-Cu is the strongest peer-reviewed peptide for skin, with collagen-density signal in cosmeceutical trials. Most dermatologists run them together. If a reader has to pick one, retinol is the workhorse with the bigger trial record.
Who wins for what
| Use case | Who wins, and why |
|---|---|
| fine lines, photoaging, cell turnover |
retinol Decades of dermatology trials show measurable wrinkle reduction and improved photodamage; tretinoin has FDA approval for photoaging. |
| collagen synthesis (head-to-head signal) |
ghk-cu Pickart's biopsy work showed 70% of GHK-Cu users had increased collagen production at one month vs 40% on retinoic acid in a small comparison. |
| tolerability, sensitive skin |
ghk-cu Retinol drives the well-known 'retinization' phase (peeling, redness, photosensitivity); GHK-Cu is generally well tolerated. |
| stack synergy |
tie - run both Different mechanisms (retinoid receptor pathway vs copper-tripeptide signaling) - many dermatologists pair them in AM/PM routines. |
What the head-to-head data shows
Retinol is not a peptide - it's a vitamin A alcohol that converts to retinoic acid in the skin. We're including it because patients comparing skin treatments ask about both. The retinoid evidence base is enormous; the foundational paper is Griffiths et al., NEJM 1993 showing tretinoin restores collagen formation in photodamaged human skin via biopsy evidence. Multiple split-face trials since (e.g. Kang et al., J Drugs Dermatol) confirmed retinol formulations approach tretinoin's effect at roughly a 10:1 dose ratio. GHK-Cu's evidence sits on Pickart's papers - Pickart and Margolina, Int J Mol Sci 2012 reviewed the molecule's signaling and skin-regenerative effects. A small biopsy comparison reported 70% of GHK-Cu subjects had increased dermal procollagen at one month vs 40% on retinoic acid (smaller cohort, narrower endpoint). Cosmeceutical trials at 1-2% topical GHK-Cu over 12 weeks consistently show firmness and elasticity improvements.
Our honest call
Retinol is the workhorse - if a reader can only run one, that's the move. The trial record is decades deep, the mechanism is well-characterized, and tretinoin (the prescription form) has FDA approval for photoaging. GHK-Cu is the better choice for sensitive skin or the user who can't tolerate retinization, and the head-to-head collagen signal is real, just on small cohorts. The pragmatic answer most dermatologists land on: retinol at night, GHK-Cu serum in the morning, sunscreen always. The combo isn't antagonistic and the mechanisms are genuinely different. Read the GHK-Cu topical skin protocol for the GHK side.
Sources and citations
- Griffiths et al., Tretinoin restores collagen in photodamaged skin, NEJM 1993 (PMID 8336687)
- Pickart and Margolina, GHK peptide review, Int J Mol Sci 2012 (PMID 22928174)
- Pickart and Margolina, GHK gene expression review, Int J Mol Sci 2018 (PMID 29487424)
- Kang et al., Retinol vs tretinoin split-face study, J Drugs Dermatol
- FDA Renova/Retin-A prescribing information (tretinoin for photoaging)
Where to go next
- Full GHK-Cu directory entry
- GHK-Cu dosing breakdown
- What are peptides - if you skipped the foundation
- All Protocol One comparisons
- How peptides actually work
- Subscribe to the dispatch
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine. None of this replaces a doctor. Peptides are gray-market in the US for most uses. Talk to a real prescriber before you change anything.